undamentalytics Newsletter
Sign in

Replimune Group, Inc. (REPL) stock

Add to watchlist

Add holding +

NASDAQ: REPL Nasdaq Biotechnology Next results ~February 2, 2027

Replimune Group, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in March.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$6.3

Forward price-to-sales vs peers

Base case. Range ~$6.3–$25. Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Replimune Group, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 7 selling0 purchases and 17 sales by directors and officers, last 12 monthsInsider trades
  • Funds142 adding, 94 cuttingOf 47 active managers that changed their stake, 21 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~February 2, 2027 (estimated)

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 32% in the quarter to 2026-09-30, the 3rd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Replimune Group, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Share dilution. Diluted shares rose 8.9% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 187% and a beta of 1.0 against the S&P 500.
  • Heavily shorted. 34.0% of the shares available to trade are sold short (11.5 days of average volume to cover).

Latest results

Earnings per share
-$0.54 against an average estimate of -$0.79: beat by 31.5%
Share reaction
+33.3% in the first session after the results on October 28, 2026, against 0.0% for the S&P 500
Next report
October 28, 2026; average EPS estimate -$0.48

Replimune Group's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+10.7%
  • 1 week+56.3%
  • 1 month+49.1%
  • This year+100.5%
  • 1 year+100.3%
  • 5 years-41.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-2.78

Growth

Share count change
+8.9%

Earnings

Last results
October 28, 2026
Next results (est.)
February 2, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Shareholder vote
  3. Results
  4. Announcement
  5. Announcement
  6. Announcement
  7. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Replimune Group, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Replimune Group, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.72 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: no revenue, margin or share count to start from
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$6.3 ~$6.5–$25 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$6.3 ~$6.3–$25 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Replimune Group, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.01 +41% $35m 0%
Next −$0.65 +68% $196m +462%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −5.6% on 90 days ago. In the last 30 days, 1 analyst raised Replimune Group, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Replimune Group, Inc., last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.13 Current fiscal year, 60 days ago: −$2.98 Current fiscal year, 30 days ago: −$3.01 Current fiscal year, 7 days ago: −$3.01 Current fiscal year, Now: −$2.01 −$2.01 Next fiscal year, 90 days ago: −$1.27 Next fiscal year, 60 days ago: −$2.04 Next fiscal year, 30 days ago: −$1.82 Next fiscal year, 7 days ago: −$1.82 Next fiscal year, Now: −$0.65 −$0.65

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.13−$1.27
60 days ago −$2.98−$2.04
30 days ago −$3.01−$1.82
7 days ago −$3.01−$1.82
Now −$2.01−$0.65

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 −$0.79 −$0.54 +31.5%
Jun 2026 −$0.77 −$0.72 +6.2%
Mar 2026 −$0.72 −$0.76 −5.6%
Dec 2025 −$0.82 −$0.77 +6.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

8 analysts, Oct 2026
Buy788%
Hold00%
Sell113%

Monthly trend

  1. Oct 20262518
  2. Sep 20262518
  3. Aug 20262518
  4. Jul 202622318

Counts of recommendations published by analysts covering Replimune Group, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
34.0%
of tradable shares
Days to cover
11.5
at average volume
Short interest, 1 month
+2%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.6%
of shares
Employees
465
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
REPL−29%+0%−69%+44%−20%+101%
Industry peers (median)−36%−57%−17%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
REPL25%50%25%58%42%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
REPL−44%−55%−77%−46%−80%−83%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since July 20, 2018: 97% from December 1, 2020 to April 13, 2026. Getting back needed a 2997% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.70 – $19.49
From 52-week high
0.0%
vs 50-day average
+42.5%
vs 200-day average
+108.3%
Volatility (1 year)
187%
Beta vs S&P 500
1.00

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±6.9%
After a week
6 up, 5 down
typical move ±7.7%
After a month
7 up, 4 down
typical move ±16.2%
Results releasedNext dayS&P 500 next day5 days21 days
October 28, 2026 +33.3% 0.0% — —
August 14, 2026 −3.7% −0.7% −2.8% −14.2%
June 29, 2026 −4.8% +2.4% −1.0% −53.5%
February 3, 2026 +0.4% −1.3% +11.8% +0.9%
November 6, 2025 −3.1% −1.0% +4.7% +25.1%
August 7, 2025 −3.8% +0.7% −2.7% +9.8%
May 22, 2025 −1.3% −0.6% +6.1% +15.2%
February 12, 2025 +11.2% +0.7% +11.4% −9.3%
November 12, 2024 −6.5% −0.3% −12.4% −2.2%
August 8, 2024 +4.1% +2.8% +12.0% +14.5%
May 16, 2024 −5.4% −0.1% −16.9% +14.7%
February 8, 2024 +4.6% +0.6% +3.2% +19.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Dividends, buybacks and capital spending

Diluted share count
+8.9%
year over year

Who owns it

Funds buying and selling
Reported value
$1.1B
Institutions reporting
198
Shares held vs prior quarter
▲ 17.7%
Positions opened / closed
71 / 51

Top buyers and sellers, Q2 2026: 142 institutions bought and 94 sold ; the biggest buyer was Boxer Capital Management, LLC (+2.8M shares) and the biggest seller Price T Rowe Associates Inc (−6.5M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Baker Bros. Advisors LP $122M 11.0M 11.6% 0.0%
Blackrock, Inc. $99.2M 9.0M 9.4% ▲ 43.6%
RTW Investments, LP $82M 7.4M 7.8% ▲ 0.7%
Ridgeback Capital Investments L.P. $80.9M 7.3M 7.7% —
Goldman Sachs Group Inc $50.3M 4.5M 4.8% ▲ 99.4%
State Street Corp $49.2M 4.4M 4.7% ▲ 17.4%
Montanova Capital, LLC $48.6M 4.4M 4.6% ▲ 4.0%
Boxer Capital Management, LLC $44.1M 4.0M 4.2% ▲ 239.0%
Vanguard Capital Management LLC $32.1M 2.9M 3.0% ▲ 5.0%
Fcpm Iii Services B.V. $31.1M 2.8M 2.9% 0.0%
AQR Capital Management LLC $28.4M 2.6M 2.7% ▲ 904.4%
Logos Global Management LP $27.7M 2.5M 2.6% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Replimune Group, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $1.9M 17 trades by 7 insiders · 14% under pre-set plans
Net ▼ $1.9M net selling
Insider Date Trade Shares Price Value
Hill Emily Luisa Chief Financial Officer August 17, 2026 Sell 9,256 $14.28 $132,176
Schwendenman Andrew Chief Accounting Officer August 10, 2026 Sell 7,632 $12.97 $98,987
Xynos Konstantinos Chief Medical Officer August 10, 2026 Sell 11,447 $12.97 $148,468
Hill Emily Luisa Chief Financial Officer August 10, 2026 Sell 11,448 $12.97 $148,481
Patel Sushil Chief Executive Officer August 10, 2026 Sell 39,341 $12.97 $510,253
Sarchi Christopher Chief Commercial Officer June 1, 2026 Sell pre-set plan 12,000 $9.24 $110,880
Hill Emily Luisa Chief Financial Officer May 18, 2026 Sell 7,812 $5.08 $39,685
Patel Sushil Chief Executive Officer May 18, 2026 Sell 37,324 $5.08 $189,606
Astley-Sparke Philip Director May 18, 2026 Sell 17,657 $5.08 $89,698
Sarchi Christopher Chief Commercial Officer May 18, 2026 Sell 8,626 $5.08 $43,820
Schwendenman Andrew Chief Accounting Officer May 18, 2026 Sell 7,894 $5.08 $40,102
Xynos Konstantinos Chief Medical Officer May 18, 2026 Sell 14,023 $5.08 $71,237

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around February 2, 2027 estimated from the company's past filing pattern, not announced

  • October 28, 2026
  • August 14, 2026
  • June 29, 2026
  • February 3, 2026
  • November 6, 2025
  • August 7, 2025

Recent SEC filings

Data status

When each part of this page on Replimune Group, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Replimune Group, Inc. in brief

What does Replimune Group, Inc. do?
Replimune Group, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in March.
What is Replimune Group, Inc.'s stock ticker?
Replimune Group, Inc. trades under the ticker REPL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Replimune Group, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Baker Bros. Advisors LP, Blackrock, Inc. and RTW Investments, LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Replimune Group, Inc. stock?
Over the last 12 months, Replimune Group, Inc.'s directors and officers reported 0 open-market purchases and 17 sales on Form 4. The insider trading page charts every trade.
When is Replimune Group, Inc.'s next earnings date?
Around February 2, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Replimune Group, Inc. announces its own schedule.